Post-IPO Equity - Protalix BioTherapeutics
Investment Firm
Overview
Protalix is a biopharmaceutical company that is revolutionizing the development and manufacturing of recombinant therapeutic proteins.
Announced Date
Feb 11, 2021
Closed on Date
Feb 18, 2021
Funding Type
Post Ipo Equity
Highlights
Location
Asia
Social
Investor Lead
N/A
Participant Investors
1
| Investor Name |
|---|
 Cybele Holdings |
Round Details and Background
Protalix BioTherapeutics raised $40000000 on 2021-02-11 in Post-IPO Equity
Protalix is a biopharmaceutical company that is revolutionizing the development and manufacturing of recombinant therapeutic proteins.
Company Funding History
9
| Announcment Date | Transaction Name | Number Of Investors | Lead Investor | Money Raised |
|---|---|---|---|---|
| Apr 08, 2008 |  Grant - Protalix BioTherapeutics | 1 | - | 4.0M |
| Oct 15, 2004 | Series B - Protalix BioTherapeutics | - | 3.5M | |
| Dec 25, 2005 | Series C - Protalix BioTherapeutics | 2 | - | 5.3M |
| Oct 14, 2015 | Post-IPO Equity - Protalix BioTherapeutics | 1 | - | 10.0M |
Recent Activity
There is no recent news or activity for this profile.